MedTrace Logo

The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication

NCT06777732 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 672

Last updated 2025-01-16

No results posted yet for this study

Summary

The purpose of this study was to compare the efficacy of 14-day eradication of Helicobacter pylori with different doses of Keverprazan combined with Amoxicillin dual therapy and Keverprazan-based bismuth quadruple therapy and compare the adverse reactions, compliance, and factors affecting the efficacy of eradication schemes among different groups.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Keverprazan

Potassium-competitive acid blocker

DRUG

Amoxicillin

Antibiotic for H. pylori eradication

DRUG

Furazolidone

Antibiotic for H. pylori eradication

DRUG

Colloidal Bismuth Pectin

Gastric mucosal protectant

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2025-09-30
Completion
2026-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06777732 on ClinicalTrials.gov